Author(s): Elena Vyacheslavna Litvinova, Olga Viktorovna Posilkina, Nataliia Fedorovna Maslova

Email(s): hlitvinova@gmail.com

DOI: 10.5958/0974-360X.2018.00566.8   

Address: Elena Vyacheslavna Litvinova1*, Olga Viktorovna Posilkina2, Nataliia Fedorovna Maslova3
1Candidate of Biology (PhD), Associate Professor of the National University of Pharmacy, National University of Pharmacy, Ukraine, 61002, Kharkov, 53 Pushkinska str.
2Doctor of Pharmacy, Professor of the National Pharmaceutical University, National University of Pharmacy, Ukraine, 61002, Kharkov, 53 Pushkinska str.
3Doctor of Biology, Professor of the State Enterprise “State Scientific Center of Drugs”, State Enterprise “State Scientific Center of Drugs”, Ukraine, 61085, Kharkov, 33 Astronomicheskaya str.
*Corresponding Author

Published In:   Volume - 11,      Issue - 7,     Year - 2018


ABSTRACT:
The aim of this study is to analyze the specificities formation of patent strategy at all stages of biosimilar development and implementation. Due to the complexity of biological medicinal product structure and the impossibility of accurate reproduction of technology, biosimilar can not be identical to a copy of the original biological medicinal product. The dependence of biological medicinal product from living cells, the functions of which inevitably vary, as well as the presence of impurities can significantly change the properties of biological medicinal product of different manufacturers. On the basis of the above, it follows that when creating a biosimilar there is a possibility of obtaining a new invention. It has established the possibility of biosimilar patent protection at all stages of the life cycle depending on the stage of preparation of registration dossier. It contributes to rational management of the intellectual capital of pharmaceutical companies and more effective drug provision of the population. It has been proved that various stages of the development and implementation of biosimilars should be accompanied by different types of their patenting (pharmaceutical composition, new dosage form, delivery method, optimization of the purification process, increase of stability, new indications for application or new treatment), etc. It has proposed author's algorithm for the formation of patent strategy of biosimilar development and implementation depending on the stage of preparation of the registration dossier.


Cite this article:
Elena Vyacheslavna Litvinova, Olga Viktorovna Posilkina, Nataliia Fedorovna Maslova. Formation of patent strategy at all stages of biosimilar development and Implementation. Research J. Pharm. and Tech 2018; 11(7): 3081-3086. doi: 10.5958/0974-360X.2018.00566.8

Cite(Electronic):
Elena Vyacheslavna Litvinova, Olga Viktorovna Posilkina, Nataliia Fedorovna Maslova. Formation of patent strategy at all stages of biosimilar development and Implementation. Research J. Pharm. and Tech 2018; 11(7): 3081-3086. doi: 10.5958/0974-360X.2018.00566.8   Available on: https://rjptonline.org/AbstractView.aspx?PID=2018-11-7-65


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available